Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

WALTHAM, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia. The grants are comprised of $1 million from the Muscular Dystrophy Association (MDA) and $125,000 from the Friedreich's Ataxia Research Foundation (FARA) and the National Ataxia Foundation (NAF). The grants will further the development, characterization and selection of a drug candidate for human clinical trials as well as support the development of tools ("biomarkers") to monitor the desired biological impact of the drugs in clinical trials.

"We are very pleased to receive support from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Foundation and the National Ataxia Foundation, national organizations recognized for their commitment to innovative research aimed at providing new therapeutic options for patients," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We believe that establishing partnerships with these non-profit organizations will result in a number of mutual benefits as the program matures and we prepare for human clinical trials."

Friedreich's ataxia is an inherited neurodegenerative disease in which a single gene defect results in inadequate production of the protein frataxin, leading to progressive damage to the nervous system and loss of muscle function. Prior research has demonstrated that production of frataxin protein can be increased in tissue samples and animal models by a family of compounds, suggesting the potential utility of these compounds in slowing or halting disease progression.

In April 2007, Re
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative ... reactive skin while battling the weakening threat of ... cream is formulated with star ingredient GLYCOSEA, a ... in a complex of soothing minerals and trace ...
(Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
(Date:4/29/2015)... ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial statements ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , 1,703 ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... Colo. , April 29, 2015 ... providers of cartilage, cellular, bone, skin and soft-tissue ... care to advance patient healing, announced the launch ... Centers for Medicare & Medicaid Services (CMS) also ... from the low-cost to the high-cost category for ...
Breaking Biology Technology:Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Sterlitech Offers New Ultrafiltration Membranes 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4AlloSource Announces New Possibilities In Wound Care 2
... steps toward putting quantum computers into real practice sending ... and transmitting the signal to a second, distant qubit ... Yale. The accomplishments are reported in sequential issues of Nature ... highlighted as the cover along with complementary work from a ...
... 3% over Fiscal 2006 to $27.5 million - ... dollars unless otherwise noted), BELLEVILLE, ON, Sept. 26 ... technology-driven Canadian,biopharmaceutical company, today announced financial results for its ... announcements of the first shipment and commercial usage of,our ...
... Sept. 26 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... in New York City on Thursday, October 4, 2007,from ... Westin New York at Times,Square, on 270 West 43rd ... C. Quay, M.D., Ph.D., Chairman, President and,Chief Executive Officer ...
Cached Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3Bioniche Reports Fiscal 2007 Year-End Results 2Bioniche Reports Fiscal 2007 Year-End Results 3Bioniche Reports Fiscal 2007 Year-End Results 4Bioniche Reports Fiscal 2007 Year-End Results 5Bioniche Reports Fiscal 2007 Year-End Results 6Bioniche Reports Fiscal 2007 Year-End Results 7Bioniche Reports Fiscal 2007 Year-End Results 8Bioniche Reports Fiscal 2007 Year-End Results 9Bioniche Reports Fiscal 2007 Year-End Results 10Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... National Human Genome Research Institute has selected the Johns ... of Excellence" to study the ethical, legal and social ... will receive three years of funding to build on ... and public health, bringing the fields together in the ...
... HUNTSVILLE, TX (9/18/12) -- To help identify victims after ... or acts of genocide, researchers at Sam Houston State ... and speed up the DNA identification process. ... adverse conditions, such as remote locations, intense heat, and ...
... well to keep patients from developing AIDS, but no one ... the human body, so patients continue to require lifelong treatment ... team of researchers led by Dr. David N. Levy, Associate ... York University College of Dentistry (NYUCD), have discovered a new ...
Cached Biology News:Personal genome, public health 2Personal genome, public health 3Sam Houston State studies DNA preservation in mass disasters 2New HIV-1 replication pathway discovered by NYU College of Dentistry researchers 2
... LM is a high quality microarray scanner based ... background rejection and spatial resolution. The DNAscope ... low cost microarray scanner that is upgradeable to ... Main Features: Includes control module (computer), ...
... Convenient, easy-to-use kits for arraying ... detection using common lab equipment. DiscoverLight ... analysis of your protein, cell lysate ... format. The kits include specially designed ...
... Stabilizer is an aqueous solution that ... other non-toxic stabilizing chemicals in a ... 6.5. This product contains ... 0.02% bromonitrodioxane as a preservative. ...
... When nonspecific binding is a problem ... variety of immobilized NeutrAvidin products as ... NeutrAvidin is a modified avidin derivative ... provide a biotin-binding protein with exceptionally ...
Biology Products: